<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902523</url>
  </required_header>
  <id_info>
    <org_study_id>HUG-116 P1</org_study_id>
    <nct_id>NCT02902523</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Safety and Pharmacokinetics of HUG116 Tablet and Viread® Tablet in Healthy Male Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huons Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huons Co.,Ltd.</source>
  <brief_summary>
    <textblock>
      A randomized, open-label, single-dosing, 2x2 crossover study to compare the safety and
      pharmacokinetics of HUG116 tablet(Tenofovir Disoproxil) with Viread® tablet(Tenofovir
      Disoproxil Fumarate) in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve(AUC)last of Tenofovir</measure>
    <time_frame>0h(before administration), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum of concentration(Cmax) of Tenofovir</measure>
    <time_frame>0h(before administration), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve(AUC)inf of Tenofovir</measure>
    <time_frame>0h(before administration), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of Tenofovir</measure>
    <time_frame>0h(before administration), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β of Tenofovir</measure>
    <time_frame>0h(before administration), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance/F of Tenofovir</measure>
    <time_frame>0h(before administration), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Viread ® tablet 300mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir disoproxil fumarate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HUG116 tablet 245mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir disoproxil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viread® tablet 300mg</intervention_name>
    <description>Single dose administration(PO) in the fasted state</description>
    <arm_group_label>Viread ® tablet 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HUG116 tablet 245mg</intervention_name>
    <description>Single dose administration(PO) in the fasted state</description>
    <arm_group_label>HUG116 tablet 245mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 19 to 45, healthy male subjects(at screening)

          -  Body weight over 55kg, in the range of calculated Ideal Body Weight ± 20%

          -  Subject without a hereditary problems, chronic disease and morbid symptom

          -  Volunteer who totally understands the progress of this clinical trials, make decision
             by his free will, and signed a consent form to follow the progress.

        Exclusion Criteria:

          -  Volunteer who has past or present history of any diseases following below.(liver,
             kidney,digestive system, pulmonary,hematooncology, endocrine, urinary,neurology,mental
             disorder, skeletomuscular, immunology, otolaryngology,cardiovascular)

          -  Volunteer who had GI tract disease(Crohn's disease, ulcer, acute or chronic
             pancreatitis) or surgery(appendectomy, hernioplasty are excluded)

          -  Volunteer who had hypersensitivity reaction to medicines including Tenofovir

          -  Volunteer who has genetic disorders such as glucose-galactose malabsorption, Lapp
             lactose deficiency, galactose intolerance

          -  Sitting systolic blood pressure &gt; 140mmHg or &lt; 100mmHg, sitting diastolic blood
             pressure ≥ 90mmHg or &lt; 60mmHg, pulse ≥ 100 beats per minute

          -  Exceed 2 times the normal range of AST, ALT, Total Bilirubin at screening test

          -  Have the result of Creatinine clearance is less than 50mL/min(Cockcroft-Gault equation
             applicable)

          -  Have the result of serum test(RPR Ab(VDRL), HBsAg, HCV Ab, Anti HIV(AIDS)) is a
             positive

          -  History of drug abuse, or a positive urine drug screen

          -  Having ETC drug or herbal medicines within 2 weeks before first administration or OTC
             drug or vitamin preparations within a week before first administration

          -  Participation in any other clinical trial involving investigational drugs within 3
             months

          -  Volunteer who had whole blood donation in 2 months, or component blood donation or
             transfusion in 1 months

          -  Regular alcohol consumption(over 21 units/week, 1unit=10g of pure alcohol) or
             volunteers who cannot abstain from drinking during the study

          -  Volunteers smoking over 10 cigarettes per day in the last 3 months and taking a
             surfeit of caffeine(caffeine&gt;400mg per day)

          -  Subjects with planning of dental treatment (tooth extraction, endodontic treatment
             etc.) and any surgery (aesthetic operation, laser in-situ keratomileusis, laser
             assisted sub-epithelial keratomileusis etc.) from signed on an informed consent form
             to post-study visit

          -  Any condition that, in the view of the investigator, would interfere with study
             participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huons</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13486</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

